Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Ken‐ichi Okada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6377-1860; OpenAlex author ID A5101613099. Sources: OpenAlex.

Their work

Papers
29
Trials
0
Grants
0
Labs led
0
Collaborators
113
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: 4 papers · 2020: 5 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 29

  1. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  2. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00432-023-05594-1↗
  3. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  4. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2023.06.012↗
  5. Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Contro… Co-author DOI 10.1097/xcs.0000000000000408↗
  6. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by… Co-author DOI 10.1245/s10434-021-10985-0↗
  7. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreat… Co-author DOI 10.1016/j.ejso.2021.06.005↗
  8. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  9. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Co-author DOI 10.1007/s00423-020-01857-4↗
  10. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Co-author DOI 10.1097/md.0000000000018718↗
  11. Preoperative In-Hospital Rehabilitation Improves Physical Function in Patients with Pancreatic Cancer Scheduled for Surgery. Co-author DOI 10.1620/tjem.251.279↗
  12. Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14399↗
  13. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Early Diagnosis of Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics10010023↗
  14. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  15. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2018.12.015↗
  16. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  17. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  18. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  19. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  20. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12013↗
  21. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Co-author DOI 10.1002/ijc.30510↗
  22. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multi… Co-author DOI 10.1159/000478660↗
  23. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11389↗
  24. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Co-author DOI 10.1007/s00280-016-3121-8↗
  25. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Co-author DOI 10.1016/j.surg.2016.02.032↗
  26. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Co-author DOI 10.1097/mpa.0000000000000634↗
  27. [Current treatment and prognosis of pancreatic cancer in Japan and Western countries]. Co-author PMID 25857010↗
  28. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗
  29. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/j.1349-7006.2012.02214.x↗

Closest collaborators

The 25 strongest of 113 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroki Yamaue · 28 shared papers, 2012–2024 · strength 2.54
  2. Manabu Kawai · 24 shared papers, 2012–2024 · strength 2.22
  3. Seiko Hirono · 22 shared papers, 2012–2023 · strength 1.98
  4. Motoki Miyazawa · 18 shared papers, 2012–2024 · strength 1.76
  5. Yuji Kitahata · 16 shared papers, 2012–2024 · strength 1.66
  6. Atsushi Shimizu · 8 shared papers, 2012–2024 · strength 0.71
  7. Sohei Satoi · 9 shared papers, 2014–2023 · strength 0.62
  8. Ippei Matsumoto · 7 shared papers, 2016–2023 · strength 0.53
  9. Hideki Motobayashi · 3 shared papers, 2022–2024 · strength 0.49
  10. Atsushi Miyamoto · 3 shared papers, 2022–2024 · strength 0.49
  11. Yoshiaki Murakami · 6 shared papers, 2016–2019 · strength 0.40
  12. Masayuki Sho · 6 shared papers, 2016–2019 · strength 0.40
  13. Michiaki Unno · 5 shared papers, 2016–2020 · strength 0.38
  14. Tomohiro Yoshimura · 2 shared papers, 2023–2024 · strength 0.33
  15. Hiroaki Yanagimoto · 5 shared papers, 2014–2019 · strength 0.31
  16. Yuki Kawaji · 3 shared papers, 2020–2021 · strength 0.30
  17. Keiichi Hatamaru · 3 shared papers, 2020–2021 · strength 0.30
  18. Masahiro Itonaga · 3 shared papers, 2020–2021 · strength 0.30
  19. Takashi Tamura · 3 shared papers, 2020–2021 · strength 0.30
  20. Yasunobu Yamashita · 3 shared papers, 2020–2021 · strength 0.30
  21. Masayuki Kitano · 3 shared papers, 2020–2021 · strength 0.30
  22. Masanao Kurata · 4 shared papers, 2016–2019 · strength 0.27
  23. Kenichiro Uemura · 4 shared papers, 2016–2019 · strength 0.27
  24. Fuyuhiko Motoi · 4 shared papers, 2016–2019 · strength 0.27
  25. Goro Honda · 4 shared papers, 2016–2019 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.